Quick answer
Why are GHK-Cu, BPC-157 and TB-500 studied together? The GLOW stack is a fixed 5:1:1 mass-ratio blend, about 17.6 : 1 : 1.6 by moles, supplied as a 70 mg co-lyophilized vial for laboratory research use only. A combination is studied to ask whether effects are additive or interact, but that needs a factorial design: each component alone, each pair, and all three, plus controls such as copper-free GHK and a copper salt. The three components have uneven evidence, and few studies test all three together, so the rationale is a design hypothesis.
Why would a laboratory study three peptides in one vial instead of three separately? The practical answer, convenience, is covered in the comparison of blend versus separate vials. This article takes the scientific question: what can a combination experiment tell you that single-compound experiments cannot, what does each component's literature actually support, and what controls does a defensible design need? It describes published preclinical and cell-based work only, makes no claim about benefits, and covers a laboratory research material supplied for laboratory research use only; not for human consumption.
What is in the vial
The GLOW stack product page lists a co-lyophilized blend of three peptides: GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg, 70 mg total, supplied as a blue lyophilized powder in a sealed clear glass research vial, with purity stated as ≥98% by HPLC and storage at 2–8 °C, or −20 °C for long-term. The GLOW blend overview describes the components in detail; here the relevant facts are the ratio and the nature of each component.
| Component | Nature | Mass per vial | Approx. molecular weight | Approx. moles per vial |
|---|---|---|---|---|
| --- | --- | --- | --- | --- |
| GHK-Cu | Tripeptide–copper(II) complex | 50 mg | ≈ 404 g/mol (complex) | ≈ 0.124 mmol |
| BPC-157 | 15-residue linear peptide | 10 mg | ≈ 1,419.5 g/mol | ≈ 0.0070 mmol |
| TB-500 | 7-residue N-acetylated peptide | 10 mg | ≈ 889.0 g/mol | ≈ 0.0112 mmol |
The mass ratio is 5:1:1, but the molar ratio is about 17.6 : 1 : 1.6, because the molecules differ so much in size. Mass and moles tell different stories, and a combination study that talks about "equal parts" without saying which is meaningless. The arithmetic is simple (moles equal mass divided by molecular weight), and it is the first calculation to do when comparing the blend against separately prepared single-compound controls.
The logic of studying combinations
A combination experiment asks one of three questions, and each demands a different design.
| Question | Meaning | Design needed |
|---|---|---|
| --- | --- | --- |
| Is the response additive? | The combined effect equals the sum of the single effects | Each component alone, at matching concentrations, plus the combination |
| Is there an interaction? | The combined effect differs from the sum | Dose-response curves for each component plus a matrix of combinations |
| Do the components act on different processes? | The endpoints respond to different members | Several endpoints measured across all arms |
The point is easy to miss: observing an effect in a blend does not show that the components interact. If the effect comes from only one component, the blend is just a more complicated way to deliver it. Only the factorial arrangement, with each component present and absent in every combination, separates the possibilities. For three components that means eight arms before replicates: nothing, each alone, each pair, and all three. A fixed-ratio vial supplies only the last arm, which is why it is a convenience format, not a substitute for the design.
What each component's literature supports
GHK-Cu
GHK is a tripeptide found in human plasma, and its ability to bind copper was described by Pickart and colleagues in 1980, who proposed that it facilitates copper uptake into cells. Later reviews by the same group (2015, 2018) summarize cell-culture and gene-expression work in dermal systems, including reported effects on collagen and glycosaminoglycan synthesis in fibroblasts and broad changes in gene expression in skin models. It is the most thoroughly documented of the three in cell-based dermal work, and for that reason it is the component whose published context is most reproducible in culture. GHK-Cu research overview covers it in more depth.
BPC-157
BPC-157 is a synthetic fragment of a gastric protein. The literature is mostly from one group, whose work is summarized in reviews of angiogenic growth factor signaling and of brain–gut axis effects (Seiwerth and colleagues, 2018; Sikiric and colleagues, 2016). It is almost entirely preclinical, in rodent and cell models. A careful reader notes that independent replication is limited, and handles the reported findings as hypotheses that need confirmation in each laboratory's own system.
TB-500
TB-500 is sold as a fragment related to thymosin beta-4, the principal G-actin-sequestering protein in many cells. Much of the published literature concerns the full thymosin beta-4 protein, not the fragment. Malinda and colleagues (1999) reported accelerated wound closure with thymosin beta-4 in rodent models, and Goldstein and colleagues (2012) reviewed its multiple cellular activities. This distinction matters: a result for the 43-residue protein cannot be assumed for a short fragment. TB-500 versus thymosin beta-4 explains the relationship.
Evidence gaps that a combination study should acknowledge
- Few or no published studies test all three components together in a defined system; the rationale for the combination is therefore a design hypothesis, not an established finding.
- The three have different evidence qualities: cell-based and gene-expression work for GHK-Cu, largely single-group rodent work for BPC-157, and full-protein data for thymosin beta-4.
- Concentrations used in published single-compound work do not map onto the fixed ratio of the blend.
- The copper in GHK-Cu is redox-active and can influence other components and assay readouts independently of the peptide.
The last point is the one most often forgotten, and it motivates a distinct control.
Controls a defensible design needs
| Control | Question it answers |
|---|---|
| --- | --- |
| Vehicle only | Baseline drift and diluent effect |
| Each component alone, at the concentration it has in the blend | Whether the blend effect is attributable to one component |
| GHK without copper | Whether the effect depends on the copper complex |
| Copper salt at the matching copper concentration | Whether free copper alone reproduces the effect |
| Each pair | Whether two components account for the effect |
| Heat-denatured or scrambled-sequence peptide | Whether activity depends on sequence |
A design with these arms is larger than most pilot experiments, and that is the point: the combination claim needs the arms. Single-vial purchases, covered in GHK-Cu, BPC-157 and TB-500 product pages, supply the individual arms, while the blend supplies the fixed-ratio arm. Concentration arithmetic for any arm is mass divided by volume, and the reconstitution calculator handles it.
Analytical consequences of combining
A blend is analytically more demanding than a single compound. Chromatography should resolve three components, and each should be identified and quantified separately; a single purity figure for a blend can conceal a shortfall in one component. Copper complexes can also behave differently from free peptides on reversed-phase columns, and metal content is measured by a different technique from peptide purity. Does copper degrade other peptides in a blend addresses the stability side, and peptide blends and research stacks gives the general framework. Receiving documentation, including the COA library where certificates are published, should be filed with the study records.
A worked example of the molar arithmetic
Suppose a laboratory wants to compare the blend with separately prepared single-compound solutions at the same molar concentration of each component. The procedure has four steps. First, dissolve the blend in a chosen volume and calculate each component's mass concentration by dividing its vial mass by that volume. Second, divide each mass concentration by the component's approximate molecular weight to get a molar concentration. Third, prepare each single-compound solution so that its molar concentration equals the corresponding value in the blend. Fourth, record the molecular weight used for each component, because the weight for the copper complex differs from the weight for the free tripeptide and the choice changes the answer by about twenty percent. That last point is a frequent source of discrepancy between papers that appear to use the same amount of GHK-Cu.
The same four steps work for the pairs: a GHK-Cu plus BPC-157 arm is prepared from the single-compound stocks at the molar concentrations they have in the blend, and the missing component is replaced by vehicle. Doing so keeps the total volume and diluent identical across arms, which removes a quiet source of variation.
Choosing between blend and separate vials
Use the fixed-ratio blend when the experiment is deliberately about that ratio, when consistency across many runs matters more than flexibility, or when the aim is to reproduce a published preparation. Use separate vials when the question is about each component or about the ratio itself. Many laboratories do both: separate vials for the factorial dissection and the blend for the confirmation arm. The principle is the same either way: say what the comparison is meant to show before choosing the format.
Frequently asked questions
What is the GLOW stack?
A co-lyophilized blend of GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg, 70 mg in total, supplied as a blue lyophilized powder for laboratory research use only.
Is the 5:1:1 ratio a mass ratio or a molar ratio?
A mass ratio. Because GHK-Cu is much smaller than the other two, the molar ratio is roughly 17.6 : 1 : 1.6 using approximate molecular weights.
Why not just buy the three peptides separately?
Separate vials allow each component to be varied independently, which a factorial design needs. A fixed blend supplies one ratio and suits experiments about that ratio or about consistency across runs.
Does a blend experiment show that the peptides interact?
Not by itself. An effect could come from one component. Showing interaction needs each component alone, each pair and the full combination, with dose-response information.
What controls are specific to a copper-peptide blend?
GHK without copper and a copper salt at the matching copper concentration, because copper is redox-active and can change assay readouts independently of the peptide.
Is there published work on all three together?
Few or no studies test all three in a defined system. The combination is a design hypothesis built from separate literatures, which differ in depth and independence.
Does TB-500 data come from thymosin beta-4 studies?
Much of the published literature concerns the full thymosin beta-4 protein. Results for the protein should not be assumed for the short fragment sold as TB-500.
How should concentrations be compared across arms?
Convert mass to moles with each component's molecular weight, then match the concentration each component has in the blend. Mass concentrations alone are misleading.
What does the blend need analytically?
Chromatography that resolves and identifies all three components, plus a separate measure of copper content, since one purity figure can hide a shortfall in one component.
Related reading: Sourcing GLOW Stack Peptide Blends: What to Verify, GLOW Stack Research Protocol: Lab Workflow and Models.
References
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987
- Pickart L, Freedman JH, Loker WJ, et al. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980;288(5792):715-717. doi:10.1038/288715a0
- Seiwerth S, Brcic L, Vuletic LB, Kolenc D, Aralica G, Misic M, et al. BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Curr Pharm Des. 2018;24(18):1972-1989. doi:10.2174/1381612824666180712110447
- Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. doi:10.2174/1570159X13666160502153022
- Malinda KM, Sidhu GS, Mani H, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. doi:10.1046/j.1523-1747.1999.00708.x
- Goldstein AL, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012;12(1):37-51. doi:10.1517/14712598.2012.634793
